Acute Myeloid Leukemia (AML)
Conditions
Keywords
adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), untreated adult acute myeloid leukemia
Brief summary
RATIONALE: PKC412 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It may also increase the effectiveness of daunorubicin and cytarabine by making cancer cells more sensitive to the drugs. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining PKC412 with chemotherapy may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best way to give PKC412 when given either after or together with daunorubicin and cytarabine in treating patients with newly diagnosed acute myeloid leukemia.
Detailed description
OBJECTIVES: Primary * Determine the safety and tolerability of PKC412 administered sequentially or concurrently with induction chemotherapy comprising daunorubicin and cytarabine followed by consolidation therapy comprising high-dose cytarabine in patients with newly diagnosed acute myeloid leukemia. * Compare the pharmacokinetics of these regimens in these patients. Secondary * Determine the efficacy of these regimens, in terms of response rate, disease-free survival, and overall survival, in these patients. * Correlate genetic variation in drug metabolism genes, leukemia genes, and drug target genes with response in patients treated with these regimens. OUTLINE: This is an open-label, multicenter study. Patients are alternately assigned to 1 of 2 induction treatment groups. * Induction therapy: * Group I (sequential therapy): Patients receive daunorubicin IV over 30 minutes on days 1-3, cytarabine IV continuously on days 1-7, and oral PKC412 twice daily on days 8-21 in the absence of disease progression or unacceptable toxicity. * Group II (concurrent therapy): Patients receive daunorubicin and cytarabine as in group I and oral PKC412 twice daily on days 1-7 and 15-21 in the absence of disease progression or unacceptable toxicity. In both groups, patients are evaluated on day 28. Patients with persistent disease receive a second induction course comprising daunorubicin IV over 30 minutes on days 1 and 2, cytarabine IV continuously on days 1-5, and oral PKC412 on the same schedule as their assigned treatment group. Patients with a complete response after course 1 or course 2 proceed to consolidation therapy. * Consolidation therapy: Patients in both groups receive high-dose cytarabine IV over 3 hours twice daily on days 1, 3, and 5 and oral PKC412 on the same schedule as their assigned treatment group. Treatment repeats every 28-42 days for 3 courses in the absence of disease progression or unacceptable toxicity. After completion of consolidation therapy, patients in both groups continue to receive PKC412 alone, according to their assigned treatment group, every 28-42 days for up to 3 years in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months.
Interventions
DRUGcytarabine
DRUGdaunorubicin hydrochloride
DRUGmidostaurin
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed acute myeloid leukemia (AML) * Newly diagnosed disease * No history of or newly diagnosed myelodysplastic syndromes, history of myeloproliferative disease, or secondary AML * No CNS malignancy PATIENT CHARACTERISTICS: Age * 18 to 60 Performance status * Karnofsky 70-100% Life expectancy * Not specified Hematopoietic * Not specified Hepatic * AST and ALT ≤ 1.5 times upper limit of normal (ULN) * Bilirubin ≤ 1.5 times ULN * No active viral hepatitis Renal * Creatinine ≤ 1.5 times ULN * No chronic renal disease Cardiovascular * Ejection fraction ≥ 50% by MUGA or echocardiogram * No congestive heart failure * No myocardial infarction within the past 6 months * No poorly controlled hypertension * No other cardiovascular disease Pulmonary * No pulmonary infiltrate, including those suspected to be infectious * Patients with pulmonary infection whose clinical symptoms have resolved are eligible provided there are no residual pulmonary infiltrates on chest x-ray Other * No gastrointestinal impairment or disease that would preclude absorption of study drugs * No uncontrolled diabetes * No active uncontrolled infection * No other disease, except carcinoma in situ, that would preclude study participation * No other severe or uncontrolled medical condition that would preclude study participation * HIV negative * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective barrier contraception during and for 3 months after study participation PRIOR CONCURRENT THERAPY: Biologic therapy * At least 5 days since prior growth factors * No concurrent biological response modifiers Chemotherapy * No prior chemotherapy * No other concurrent chemotherapy Endocrine therapy * Not specified Radiotherapy * No prior radiotherapy except radiation castration * No concurrent radiotherapy Surgery * More than 14 days since prior surgical procedure except central venous catheter placement or other minor procedure (e.g., skin biopsy) Other * More than 30 days since prior investigational agents * No other concurrent anticancer agents * No other concurrent investigational drugs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete Response (CR) rate | cycle 1, day 14, cycle day 21 - 28, end of each cycle | cycle = between 28 days and 42 days in duration |
Secondary
| Measure | Time frame |
|---|---|
| CR rate by FLT3 mutation and treatment arm | CR:cycle 1, day 14, cycle day 21 - 28, end of each cycle, FLT3: monthly |
| Overall survival by FLT3 mutation status | time of death of any cause(FLT# - minthly) |
Countries
Germany, United States
Outcome results
None listed